Axsome Therapeutics’s Earnings: A Preview

Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings report on Monday, 2023-02-27. Here’s what investors…

Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings report on Monday, 2023-02-27. Here’s what investors need to know before the announcement.

Analysts estimate that Axsome Therapeutics will report an earnings per share (EPS) of $-1.14.

Axsome Therapeutics bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $0.01, which was followed by a 11.69% increase in the share price the next day.

Here’s a look at Axsome Therapeutics’s past performance and the resulting price change:

Quarter Q3 2022 Q2 2022 Q1 2022 Q4 2021
EPS Estimate -1.08 -1.24 -1 -1.03
EPS Actual -1.07 -1.06 -1.03 -0.90
Price Change % 11.69% 8.04% 5.29% 1.52%

eps graph

Stock Performance

Shares of Axsome Therapeutics were trading at $61.93 as of February 23. Over the last 52-week period, shares are up 117.77%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Axsome Therapeutics visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

US Stock Futures Signal Lower Start On Wall Street; Verizon, American Express Earnings In Focus

Pre-open movers U.S. stock futures traded lower in early pre-market trade on Friday after closing lower in the previous session. The Dow Jones dropped by 90 points on Thursday. US initial jobless claims declined by 12,000 to 214,000 in the week ending October 15th, compared to market estimates of 230,000.

AXP